Статья

IBD patients could be silent carriers for novel coronavirus and less prone to its severe adverse events: True or False?

S. Ghavami, S. Shahrokh, N. Hossein-Khannazer, A. Shpichka, H. Aghdaei, P. Timashev, M. Vosough,
2020

Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract. The goal of IBD treatment is to reduce the inflammation period and induce long-term remission. Use of anti-inflammatory drugs including corticosteroids, immunosuppressants and biologicals, is often the first step in the treatment of IBD. Therefore, IBD patients in pandemic of infectious diseases are considered a high-risk group. The public believes that IBD patients are at a higher risk in the current coronavirus 2 pandemic. Nevertheless, these patients may experience mild or moderate complications compared to healthy people. This might be because of particular anti-TNF-α treatment or any immunosuppressant that IBD patients receive. Moreover, these patients might be silent carrier for the virus.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2020-09-01

Метаданные

Об авторах
  • S. Ghavami
    SBUMS Research Center for Gastroenterology and Liver Diseases, SBUMS Research Center for Gastroenterology and Liver Diseases
  • S. Shahrokh
    SBUMS Research Center for Gastroenterology and Liver Diseases, SBUMS Research Center for Gastroenterology and Liver Diseases
  • N. Hossein-Khannazer
    SBUMS Research Center for Gastroenterology and Liver Diseases, SBUMS School of Medicine
  • A. Shpichka
    Sechenov First Moscow State Medical University, Lomonosov Moscow State University
  • H. Aghdaei
    SBUMS Research Center for Gastroenterology and Liver Diseases, SBUMS Research Center for Gastroenterology and Liver Diseases
  • P. Timashev
    Sechenov First Moscow State Medical University, Lomonosov Moscow State University
  • M. Vosough
    Royan Institute
Название журнала
  • Cell Journal
Том
  • 22
Страницы
  • 151-154
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus